Apogee Therapeutics (APGE) Non-Current Assets (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Non-Current Assets data on file, last reported at $219.9 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 14.13% year-over-year to $219.9 million in Q1 2026; TTM through Mar 2026 was $643.3 million, a 17.25% decrease from a year earlier, with the FY2025 full-year figure at $195.8 million, down 12.69% from the prior year.
• Non-Current Assets for Q1 2026 stood at $219.9 million, up from $195.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for APGE reached as high as $241.8 million in Q3 2024 and fell as low as $3.0 million in Q4 2023.
• Historically, Non-Current Assets has averaged $142.7 million across 4 years, with a median of $167.1 million in 2025.
• Across the five-year window, Non-Current Assets soared 7387.08% in 2024 and slumped 64.41% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $3.0 million in 2023, then surged by 7387.08% to $224.2 million in 2024, then retreated by 12.69% to $195.8 million in 2025, then gained by 12.3% to $219.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $219.9 million in Q1 2026, $195.8 million in Q4 2025, and $86.1 million in Q3 2025.